After stereotactic body radiation therapy for hepatocellular carcinoma, magnetic resonance response evolved over months, making early enhancement alone unreliable.
Carbon fiber-reinforced polyetheretherketone implants consistently reduced imaging artifacts and dosimetric uncertainty versus titanium, but clinical outcome evidence remains limited.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
No single patient-specific quality assurance method covered all stereotactic radiotherapy risks, supporting combinations of measurement, independent calculation, imaging, and monitoring.
Regional lymph node irradiation was linked to attenuated local cytokine shifts and nodal damage and cell-death signatures after sinonasal stereotactic radiotherapy.
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Splitting eight fractions between inhale and exhale breath-holds reduced maximum rib dose from 67.9 to 33.5 Gy without compromising target coverage.
Multimodal registration, motion management, and arrhythmia substrate definition were the highest-risk steps in stereotactic arrhythmia radioablation.
Lot-to-lot density variation in lung-equivalent inserts reduced planning target volume coverage by up to 3%, exceeding the stated clinical tolerance.
A single 19-Gy fraction achieved 92.9% three-year biochemical relapse-free survival with limited grade 2 gastrointestinal and genitourinary toxicity.